Company & Sponsor Intelligence
University Hospital, Caen
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting0
Completed5
Countries1
Therapeutic footprint
alzheimersautismepilepsyout_of_scopeschizophrenia
Indexed studies
NCT01638884Prospective Memory Imaging
alzheimers · FranceNA
alzheimers · FranceNA
NCT02265094Associative Memory in Autism Spectrum Disorder
autism · FranceNA
autism · FranceNA
NCT01022489High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled Study
schizophrenia · FrancePHASE2, PHASE3
schizophrenia · FrancePHASE2, PHASE3
NCT01212211Hyponatremia in the Elderly: Benefit From a Change in Drug Therapy?
out_of_scope · FranceNA
out_of_scope · FranceNA
NCT06053918Research-Action in Hematology From Hospitalization to Home
out_of_scope · FranceCOMPLETED
out_of_scope · FranceCOMPLETED
NCT02832349Impact of Educational Actions on the Quality Of Life of Epileptic Patients
epilepsy · FranceNA
epilepsy · FranceNA
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →